Vivo Capital

Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform spanning venture capital, growth equity, buyout, and public equities. The Firm has approximately $6.1 billion in regulatory assets under management and has invested in over 460 public and private companies globally. Headquartered in Palo Alto, California, with additional offices in Asia, the Vivo team consists of more than 70 multidisciplinary professionals. Vivo invests broadly in healthcare across multiple sub-sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets globally. Investment Strategy Venture Capital Vivo Innovation Fund focuses on investing in venture-stage companies with the potential to develop game-changing healthcare technologies or products. Private Equity Vivo Capital’s private equity strategy is focused particularly on underwriting the operational and commercial scale-up of companies with attractive growth prospects. Vivo’s growth capital strategy focuses on providing capital to companies at critical stages in their lifecycle to catalyze or accelerate commercial growth, whereas the buyout strategy will focus on situations (e.g., leveraged buyouts, management buyouts, spin-offs, restructurings, etc.) where a controlling stake can be acquired. Public Equity Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare, and life science companies. The fund is long-only and often invests directly into companies through various financing structures, including follow-ons, PIPEs, registered directs, and IPOs.